Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period

Next Previous
Search
Trial Profile

Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclatasvir (Primary) ; Ribavirin; Simeprevir; Sofosbuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 03 May 2016 Status changed from active, no longer recruiting to completed.
  • 17 Apr 2016 Results of the sustained virologic response at 12 weeks post treatment (n=226) presented at The International Liver Congress 2016.
  • 08 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016, as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top